Biogen Inc. (NASDAQ: BIIB) controls over 30% of market share in the $19 billion (and growing) multiple sclerosis drug market, but a recent decision to abandon development of MT-1303 calls into question whether or not Biogen can maintain its dominance in the indication over time — especially due to advancing MS programs at competitors Novartis (NYSE: NVS) and Celgene (NASDAQ: CELG).
Image source: Biogen, Inc.